Research library / NAD+ (NR, NMN)

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

L Yi, A Maier, R Tao, Z Lin, A Vaidya, S Pendse et al.. GeroScience. 2023.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

NMN up to 900 mg per day was safe and raised blood NAD; 600 mg showed the best results.

Limits

Short; industry funded.

Source

doi.org/10.1007/s11357-022-00705-1 · PubMed 36482258 · Free full text

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.